Launches proposed public offering of common stock and pre-funded warrants; Terms undisclosed
Plans to grant underwriters a 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. - Intends to use net proceeds, with existing cash, cash equivalents and marketable securities, to fund ongoing clinical development and pre-commercial activities for NGN-401, plus working capital and general corporate purposes. - Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are joint bookrunning managers.
Plans to grant underwriters a 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. - Intends to use net proceeds, with existing cash, cash equivalents and marketable securities, to fund ongoing clinical development and pre-commercial activities for NGN-401, plus working capital and general corporate purposes. - Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are joint bookrunning managers.